Sofosbuvir/ledipasvir plus ribavirin achieves high SVR12 in genotype‐3 patients with compensated cirrhosis and similar to sofosbuvir plus daclatasvir: a multicentre real life cohort

Riveiro-Barciela, M.; Alonso, Sonia; Fernández, Inmaculada; Rincón, Diego; Real, Yolanda; Crespo, Javier; Gea, Francisco; Olveira, Antonio; Calleja, J.L.; Polo-Lorduy, B.; Carrión, J.A.; Arenas, J.; Devesa, M.J.; Baliellas, C.; Castro-Iglesias, Ángeles; Romero-Gómez, Manuel; Granados, R.; Pascasio, J.M.; Forns, Xavier; Turnes, Juan; Montero, J.L.; Esteban, R.; Fernández-Rodríguez, Conrado M.

Título

Fecha

2016-10

Cita bibliográfica

Riveiro-Barcela M, Alonso S, Fernández I, et al. Sofosbuvir/ledipasvir plus ribavirin achieves high SVR12 in genotype‐3 patients with compensated cirrhosis and similar to sofosbuvir plus daclatasvir: a multicentre real life cohort. En: The 67th Annual Meeting of the American Association for the Study of Liver Diseases: the Liver Meeting 2016; 2016 Nov 11-15; Boston, Massachusetts. Hoboken, NJ: John Wiley & Sons; 2016. p. 464A (Heaptology. 2016; 64 Special issue 1)

Descripción

Poster abstract

Versión del editor

https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.28798

Derechos

This is the peer reviewed version of the article which has been published in final form at Hepatology. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archiving